Zobrazeno 1 - 10
of 176
pro vyhledávání: '"RENHUA GUO"'
Autor:
Shun Lu, Xiaorong Dong, Hong Jian, Jianhua Chen, Gongyan Chen, Yuping Sun, Yinghua Ji, Ziping Wang, Jianhua Shi, Junguo Lu, Shaoshui Chen, Dongqing Lv, Guojun Zhang, Chunling Liu, Juan Li, Xinmin Yu, Zhong Lin, Zhuang Yu, Zhehai Wang, Jiuwei Cui, Xingxiang Xu, Jian Fang, Jifeng Feng, Zhi Xu, Rui Ma, Jie Hu, Nong Yang, Xiangdong Zhou, Xiaohong Wu, Chengping Hu, Zhihong Zhang, You Lu, Yanping Hu, Liyan Jiang, Qiming wang, Renhua Guo, Jianying Zhou, Baolan Li, Chunhong Hu, Wancheng Tong, Helong Zhang, Lin Ma, Yuan Chen, Zhijun Jie, Yu Yao, Longzhen Zhang, Jie Weng, Weidong Li, Jianping Xiong, Xianwei Ye, Jianchun Duan, Haihua Yang, Meili Sun, Hongying Wei, Jiawei Wei, Zheyu Zhang, Qiong Wu
Publikováno v:
Cancer Communications, Vol 44, Iss 9, Pp 1005-1017 (2024)
Abstract Background The initial randomized, double‐blinded, actively controlled, phase III ANEAS study (NCT03849768) demonstrated that aumolertinib showed superior efficacy relative to gefitinib as first‐line therapy in epidermal growth factor re
Externí odkaz:
https://doaj.org/article/2b6ae05d34ee40d883ed46122a1d5428
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Metastasis is the primary cause of lung cancer-related death. Primary cancer cells invade through the lymphatic or blood vessels to distant sites. Recently, it was proposed that lymphatic metastasis was more a hallmark of tumor aggressive
Externí odkaz:
https://doaj.org/article/13560350b2144457b71ab1d6a8828e84
Autor:
Ran Li, Hongge Liang, Jun Li, Zhenyu Shao, Donghong Yang, Jing Bao, Keqiang Wang, Wen Xi, Zhancheng Gao, Renhua Guo, Xinlin Mu
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background Paclitaxel liposome (Lipusu) is known to be effective in non-small cell lung cancer (NSCLC) as first-line treatment. This study aimed to evaluate the effectiveness and safety of paclitaxel liposome based chemotherapy plus PD-1/PD-
Externí odkaz:
https://doaj.org/article/10b2d29493044e9ab0d78e63f3417e2b
Autor:
Yanan Cui, Jun Li, Pengpeng Zhang, Dandan Yin, Ziyu Wang, Jiali Dai, Wei Wang, Erbao Zhang, Renhua Guo
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-18 (2023)
Abstract Background Invasive adenocarcinoma (IAC), which is typically preceded by minimally invasive adenocarcinoma (MIA), is the dominant pathological subtype of early-stage lung adenocarcinoma (LUAD). Identifying the molecular events underlying the
Externí odkaz:
https://doaj.org/article/133c4e9c7813470bb20e45ec9117b7f7
Publikováno v:
Cell Death and Disease, Vol 14, Iss 5, Pp 1-14 (2023)
Abstract Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment prolongs the survival of lung cancer patients harbouring activating EGFR mutations. However, resistance to EGFR-TKIs is inevitable after long-term treatment. Mol
Externí odkaz:
https://doaj.org/article/ee60bf2a8ba8465eb03763a90082c5d3
Publikováno v:
Thoracic Cancer, Vol 14, Iss 6, Pp 535-543 (2023)
Abstract Background The combination of antiangiogenic agents with epidermal growth factor receptor inhibitors (EGFR‐TKIs) and chemotherapy with EGFR‐TKIs are the most common combination treatment options in epidermal growth factor receptor (EGFR)
Externí odkaz:
https://doaj.org/article/cc5460575a6e44588fda0ea9c982c54a
Autor:
Lili XU, Renhua GUO
Publikováno v:
Chinese Journal of Lung Cancer, Vol 25, Iss 12, Pp 852-861 (2022)
Background and objective The prognosis of stage I non-small cell lung cancer (NSCLC) is generally good. However, some of the stage I NSCLC patients still may have early recurrence and metastasis, and there is no standard method to screen this part of
Externí odkaz:
https://doaj.org/article/67d4f122e2bb4aee950abd9afd79e3b4
Autor:
Shun Lu, PhD, MD, Zhiwei Chen, MD, Jiuwei Cui, MD, Renhua Guo, MD, Ziming Li, MD, Benjamin Xiaoyi Li, PhD, Xiangrong Dai, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 4, Pp 100478- (2023)
Introduction: The study (ClinicalTrials.gov, NCT04346914) is an open label, single-arm, phase 1b clinical trial investigating the safety, tolerability, and efficacy of the recombinant human anti–programmed death-ligand 1 monoclonal antibody socazol
Externí odkaz:
https://doaj.org/article/32d4080e546746b8a96ff2bcd272221d
Publikováno v:
Molecular Cancer, Vol 21, Iss 1, Pp 1-12 (2022)
Abstract Ferroptosis is an intracellular iron-dependent form of cell death that is distinct from apoptosis, necrosis, and autophagy. Extensive studies suggest that ferroptosis plays a pivotal role in tumor suppression, thus providing new opportunitie
Externí odkaz:
https://doaj.org/article/be2158a8468a41889cfe7b5db3db1d58
Autor:
Tao Jiang, Jianhua Chen, Xingxiang Xu, Ying Cheng, Gongyan Chen, Yueyin Pan, Yong Fang, Qiming Wang, Yunchao Huang, Wenxiu Yao, Rui Wang, Xingya Li, Wei Zhang, Yanjun Zhang, Sheng Hu, Renhua Guo, Jianhua Shi, Zhiwu Wang, Peiguo Cao, Donglin Wang, Jian Fang, Hui Luo, Yi Geng, Chunyan Xing, Dongqing Lv, Yiping Zhang, Junyan Yu, Shundong Cang, Yaxi Zhang, Jiao Zhang, Zeyu Yang, Wei Shi, Jianjun Zou, Caicun Zhou, Shengxiang Ren
Publikováno v:
Molecular Cancer, Vol 21, Iss 1, Pp 1-12 (2022)
Abstract Background Camrelizumab plus chemotherapy significantly prolonged progression-free survival (PFS) and overall survival (OS) compared to chemotherapy alone as first-line treatment in advanced lung squamous cell carcinoma (LUSC) in the phase I
Externí odkaz:
https://doaj.org/article/e3a7e17ca1784e8baad00d8ae21907c5